Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TVTX Stock Forecast 2026-2027
$34.10
Current Price
$3.05B
Market Cap
Buy 13
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to TVTX Price Targets
+43.7%
To High Target of $49.00
+23.2%
To Median Target of $42.00
-9.1%
To Low Target of $31.00
TVTX Price Momentum
-4.7%
1 Week Change
-2.1%
1 Month Change
+83.4%
1 Year Change
-10.8%
Year-to-Date Change
-19.1%
From 52W High of $42.13
+164.1%
From 52W Low of $12.91
📊 TOP ANALYST CALLS
Did TVTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Travere is one of their latest high-conviction picks.
Latest TVTX Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, TVTX has a bullish consensus with a median price target of $42.00 (ranging from $31.00 to $49.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $34.10, the median forecast implies a 23.2% upside. This outlook is supported by 13 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Greg Harrison at Scotiabank, suggesting a 9.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TVTX Analyst Ratings
13
Buy
2
Hold
0
Sell
TVTX Price Target Range
Low
$31.00
Average
$42.00
High
$49.00
Current: $34.10
Latest TVTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TVTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Nov 4, 2025 | Piper Sandler | Allison Bratzel | Neutral | Maintains | $35.00 |
| Oct 31, 2025 | TD Cowen | Tyler Van Buren | Buy | Maintains | $40.00 |
| Sep 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Sep 12, 2025 | Stifel | Alex Thompson | Hold | Maintains | $25.00 |
| Sep 11, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $35.00 |
| Sep 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Sep 3, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $47.00 |
| Aug 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $47.00 |
| Aug 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $32.00 |
| Aug 7, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $31.00 |
| Jul 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Assumes | $30.00 |
| Jun 11, 2025 | Citigroup | Carly Kenselaar | Buy | Maintains | $32.00 |
| Jun 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Assumes | $30.00 |
| May 16, 2025 | Wedbush | Laura Chico | Outperform | Reiterates | $30.00 |
| May 2, 2025 | Wedbush | Laura Chico | Outperform | Reiterates | $30.00 |
| May 2, 2025 | Stifel | Alex Thompson | Hold | Maintains | $23.00 |
| Apr 23, 2025 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $N/A |
| Apr 14, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $47.00 |
| Apr 10, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $47.00 |
Travere Therapeutics Inc. (TVTX) Competitors
The following stocks are similar to Travere based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Travere Therapeutics Inc. (TVTX) Financial Data
Travere Therapeutics Inc. has a market capitalization of $3.05B with a P/E ratio of -8.4x. The company generates $435.83M in trailing twelve-month revenue with a -20.3% profit margin.
Revenue growth is +162.1% quarter-over-quarter, while maintaining an operating margin of +15.1% and return on equity of -410.8%.
Valuation Metrics
Market Cap
$3.05B
Enterprise Value
$3.17B
P/E Ratio
-8.4x
PEG Ratio
0.1x
Price/Sales
7.1x
Growth & Margins
Revenue Growth (YoY)
+162.1%
Gross Margin
+99.0%
Operating Margin
+15.1%
Net Margin
-20.3%
EPS Growth
+162.1%
Financial Health
Cash/Price Ratio
+8.3%
Current Ratio
2.7x
Debt/Equity
448.2x
ROE
-410.8%
ROA
-10.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Travere Therapeutics Inc. (TVTX) Business Model
About Travere Therapeutics Inc.
What They Do
Develops therapies for rare diseases.
Business Model
Travere Therapeutics generates revenue by developing and commercializing innovative therapies specifically targeting rare diseases, particularly in nephrology and hepatology. The company collaborates with healthcare professionals and researchers to create drug candidates aimed at filling the gaps in treatment options for complex conditions like focal segmental glomerulosclerosis and Alport syndrome.
Additional Information
With a focus on addressing unmet medical needs, Travere Therapeutics positions itself as a leader in the biotech industry, emphasizing the importance of research and innovation to improve patient outcomes in niche medical areas with few existing therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
385
CEO
Dr. Eric M. Dube Ph.D.
Country
United States
IPO Year
2003
Website
www.travere.comTravere Therapeutics Inc. (TVTX) Latest News & Analysis
Latest News
Quick Summary
Travere Therapeutics' CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PT. A live webcast will be available on their Investor page.
Why It Matters
Eric Dube's presentation at a major healthcare conference could indicate upcoming developments or strategies for Travere Therapeutics, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
An analyst suggests that the company's Filspari could be a blockbuster if it receives FDA approval for a new indication, with a decision expected soon.
Why It Matters
FDA approval for Filspari could significantly boost the company's revenue and stock price, presenting a potential investment opportunity or risk depending on the outcome.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Travere Therapeutics granted 20,300 inducement RSUs to five new employees on December 10, 2025, under its 2018 Equity Incentive Plan, outside the plan's standard provisions.
Why It Matters
The grant of RSUs to new employees indicates company growth and potential talent attraction, which can enhance operational efficiency and future profitability, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The biotech sector started December weakly, with IBB and XBI ETFs dropping over 2%. However, small biotech stocks have surged since mid-September, driven by increased M&A activity and buyout premiums.
Why It Matters
The biotech sector's recent volatility and M&A activity indicate potential investment opportunities, highlighting small and midcap stocks' attractiveness for future growth and returns.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Travere Therapeutics (TVTX) rose ~107% since the last 'Buy' rating, driven by FILSPARI's performance and FDA REMS changes, boosting its market cap and improving commercial prospects.
Why It Matters
Travere Therapeutics' surge signals strong market confidence in FILSPARI's performance and regulatory improvements, enhancing its commercial viability and potential for growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Armistice Capital sold 2.15 million shares of Travere Therapeutics for $29.3 million in Q3, holding 6.7 million shares worth $160.7 million at quarter-end.
Why It Matters
Armistice Capital's significant share sale in Travere Therapeutics indicates potential volatility and changes in investor sentiment, impacting stock performance and market perception.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About TVTX Stock
What is Travere Therapeutics Inc.'s (TVTX) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Travere Therapeutics Inc. (TVTX) has a median price target of $42.00. The highest price target is $49.00 and the lowest is $31.00.
Is TVTX stock a good investment in 2026?
According to current analyst ratings, TVTX has 13 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TVTX stock?
Wall Street analysts predict TVTX stock could reach $42.00 in the next 12 months. This represents a 23.2% increase from the current price of $34.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Travere Therapeutics Inc.'s business model?
Travere Therapeutics generates revenue by developing and commercializing innovative therapies specifically targeting rare diseases, particularly in nephrology and hepatology. The company collaborates with healthcare professionals and researchers to create drug candidates aimed at filling the gaps in treatment options for complex conditions like focal segmental glomerulosclerosis and Alport syndrome.
What is the highest forecasted price for TVTX Travere Therapeutics Inc.?
The highest price target for TVTX is $49.00 from at , which represents a 43.7% increase from the current price of $34.10.
What is the lowest forecasted price for TVTX Travere Therapeutics Inc.?
The lowest price target for TVTX is $31.00 from Greg Harrison at Scotiabank, which represents a -9.1% decrease from the current price of $34.10.
What is the overall TVTX consensus from analysts for Travere Therapeutics Inc.?
The overall analyst consensus for TVTX is bullish. Out of 21 Wall Street analysts, 13 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $42.00.
How accurate are TVTX stock price projections?
Stock price projections, including those for Travere Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 8:10 AM UTC